Pulmonary Metastases From Soft Tissue Sarcoma
- 1 May 1999
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 229 (5), 602
- https://doi.org/10.1097/00000658-199905000-00002
Abstract
To report the patterns of disease and postmetastasis survival for patients with pulmonary metastases from soft tissue sarcoma in a large group of patients treated at a single institution. Clinical factors that influence postmetastasis survival are analyzed. For patients with soft tissue sarcoma, the lungs are the most common site of metastatic disease. Although pulmonary metastases most commonly arise from primary tumors in the extremities, they may arise from almost any primary site or histology. To date, resection of disease has been the only effective therapy for metastatic sarcoma. From July 1982 to February 1997, 3149 adult patients with soft tissue sarcoma were admitted and treated at Memorial Sloan-Kettering Cancer Center. During this interval, 719 patients either developed or presented with lung metastases. Patients were treated with resection of metastatic disease whenever possible. Disease-specific survival was the endpoint of the study. Time to death was modeled using the method of Kaplan and Meier. The association of factors to time-to-event endpoints was analyzed using the log-rank test for univariate analysis and the Cox proportional hazards model for multivariate analysis. The overall median survival from diagnosis of pulmonary metastasis for all patients was 15 months. The 3-year actuarial survival rate was 25%. The ability to resect all metastatic disease completely was the most important prognostic factor for survival. Patients treated with complete resection had a median survival of 33 months and a 3-year actuarial survival rate of 46%. For patients treated with nonoperative therapy, the median survival was 11 months. A disease-free interval of more than 12 months before the development of metastases was also a favorable prognostic factor. Unfavorable factors included the histologic variants of liposarcoma and malignant peripheral nerve tumors and patient age older than 50 years at the time of treatment of metastasis. Resection of metastatic disease is the single most important factor that determines outcome in these patients. Long-term survival is possible in selected patients, particularly when recurrent pulmonary disease is resected. Surgical excision should remain the treatment of choice for metastases of soft tissue sarcoma to the lung.Keywords
This publication has 20 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Soft tissue sarcomas.1996
- Surgical treatment of pulmonary metastases from soft tissue sarcomas: A retrospective study in the NetherlandsJournal of Surgical Oncology, 1994
- Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcomaCancer, 1994
- Development and Treatment of Pulmonary Metastases in Adult Patients with Extremity Soft Tissue SarcomaAnnals of Surgery, 1993
- Resection of Lung Metastases From Soft-Tissue SarcomasArchives of Surgery, 1992
- Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastasesThe Annals of Thoracic Surgery, 1991
- Metastatic Patterns in Soft-Tissue SarcomasArchives of Surgery, 1983
- Pulmonary resection for metastatic nonosteogenic sarcomaCancer, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958